



Evolva shareholders approve all Board proposals in AGM

Green light for Abunda acquisition

Reinach, Switzerland, 18 May 2011 – The Annual General Meeting of **Evolva Holding SA** (SIX: EVE) has approved all proposals put forward by the Board of Directors, including those regarding the Company's intended acquisition of its R&D partner Abunda Nutrition, Inc.

A total of 85 shareholders were present at the meeting which took place in Basel today. 100,379,115 shares were represented, or 71.9% of the total number of shares issued (139,665,164). A detailed overview of the agenda items and the proposals is available on the [Evolva website](#).

The AGM proposals included increases in conditional and authorised capital in Evolva's Articles of Association. The shareholders' approval of these items clears the way for the closing of Evolva's acquisition of Abunda Nutrition, Inc. This transaction is expected to take place around the end of June 2011.

- ends -

About Evolva

Evolva is an international, innovative synthetic biology company with a world-class research platform. Evolva strives to improve people's lives by applying its technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial economy of patients, consumers and partner companies around the world. Evolva uses biosynthetic and evolutionary technologies to artificially create and optimise small molecule compounds and their production routes. Our approach differs from that of the mainstream in the pharmaceutical and chemical industries. We have discovery partnerships ongoing both in pharma and in nutrition. In addition we have a pipeline of promising compounds aimed at infectious and cardio-renal indications. For more information visit www.evolva.com.

Contact Details

Evolva

Neil Goldsmith, CEO
neilg@evolva.com
+ 41 61 485 2005

Jakob Dynnes Hansen, CFO
jakobdh@evolva.com
+ 41 61 485 2034

Paul Verbraeken, IR
paulv@evolva.com
+ 41 61 485 2035

Capital MSL

Mary Clark, Justine Lamond and Hollie Vile
evolva@capitalmsl.com
+44 (0)20 7307 5337

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.